Sees Q2 adjusted EBITDA $7M-$9M.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFMD:
- LifeMD options imply 12.4% move in share price post-earnings
- Is LFMD a Buy, Before Earnings?
- Unusually active option classes on open April 30th
- LifeMD’s Strategic Growth: Buy Rating Backed by Wegovy Integration and Future Offerings
- HIMS Stock Soars 27% as Novo Nordisk (NVO) Expands Wegovy Access to Telehealth